Loading patent…
AssigneeMerck & Co., Inc.
InventorsRichard D. Tillyer, Paul J. Reider, Edward J. J. Grabowski, Feng Xu, Jose M. Vega, Mandana Asgharnejad
Estimating the term…
The instant invention provides methods and pharmaceutical compositions for inhibiting HMG-CoA reductase, as well as for treating and/or reducing the risk for diseases and conditions affected by inhibition of HMG-CoA reductase, comprising orally administering a therapeutically effective amount of a compound selected from a dihydroxy open acid statin and a pharmaceutically acceptable salt or ester thereof in a delayed-release pharmaceutical dosage form to a patient in need of such treatment wherein substantial release of the compound from the dosage form is delayed until after passage of the dosage form through the stomach.
An oral pharmaceutical composition comprising a therapeutically effective amount of a compound selected from a dihydroxy open acid statin and a pharmaceutically acceptable salt or ester thereof and a pharmaceutically acceptable carrier, formulated as a delayed-release dosage form wherein substantial release of the compound from the dosage form after oral administration to a patient is delayed until after passage of the dosage form through the stomach.
An oral pharmaceutical composition made by combining a therapeutically effective amount of a compound selected from a dihydroxy open acid statin and a pharmaceutically acceptable salt or ester thereof with a pharmaceutically acceptable carrier in a delayed-release dosage form.
A process for preparing an oral pharmaceutical composition comprising combining a compound selected from a dihydroxy open acid statin and a pharmaceutically acceptable salt or ester thereof with a pharmaceutically acceptable carrier in a delayed-release dosage form.
Dependencies are inferred from the claim text.